Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Published version of a preprint
The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
Immunotherapy has recently entered a renaissance phase with the approval of multiple agents for the treatment of cancer. Immunotherapy stands ready to join traditional modalities, including surgery, chemotherapy, radiation, and hormone therapy, as a pillar of cancer treatment. Although immunotherapy has begun to have success in advanced cancer treatment, its scheduling and efficacy with surgery to treat earlier stages of cancer and prevent distant metastases have not been systematically examined. Here, we have used two models of spontaneously metastatic breast cancers in mice to illustrate the significantly greater therapeutic power of neoadjuvant, compared with adjuvant, immunotherapies in the context of primary tumor resection. Elevated and sustained peripheral tumor-specific immune responses underpinned the outcome, and blood sampling of tumor-specific CD8+ T cells immediately prior to and post surgery may provide a predictor of outcome. These data now provide a strong rationale to extensively test and compare neoadjuvant immunotherapy in humans. Significance: We demonstrate the significantly greater therapeutic efficacy of neoadjuvant, compared with adjuvant, immunotherapies to eradicate distant metastases following primary tumor resection. Elevated and sustained peripheral tumor-specific immune responses underpinned the outcome, and blood sampling of tumor-specific CD8+ T cells immediately prior to and post surgery may provide a predictor of outcome. Cancer Discov; 6(12); 1382–99. ©2016 AACR. See related commentary by Melero et al., p. 1312. This article is highlighted in the In This Issue feature, p. 1293
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Data from a landmark study using an orthotopic model of breast cancer showed that neoadjuvant ICIs might outperform adjuvant ICIs106.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [106]
In the citing paper
“Delivering ICIs after surgery enabled T cell expansion, and yielded the best antitumour activity while also decreasing toxicity106.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [106]
Citations
Cites
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Cited by
Items 601–700 of 930
Facts and Hopes in Radioimmunotherapy for Localized Stages of Cancer
Bosi, C., Ho, A. Y., Gregucci, F., & Formenti, S. C. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1603 · Cited by 6
Seclì, L., Nocchi, L., Leoni, G., Cotugno, G., Troise, F., Romano, G., Busiello, T., Micarelli, E., Garzia, I., Antonucci, L., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013035 · Cited by 6
“23 The superiority of neoadjuvant versus adjuvant immunotherapy has been demonstrated in preclinical models of breast cancer, where the administration of CPI before surgery was associated with higher and sustained peripheral tumor-specific immune responses.”
Sanmamed, M. F., de Andrea, C. E., Ruiz-Guillamon, D., Rodriguez-Ruiz, M. E., Ortego, I., Eguren‐Santamaría, I., Benito, A., López‐Janeiro, Á., Gomariz, J. G., Villalba-Esparza, M., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-2502 · Cited by 5
Pipe dream to pipeline: Journey of cancer vaccines and the road ahead
Onkar, S., Bozkus, C. C., Saxena, M., & Bhardwaj, N. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102575 · Cited by 7
mRNA and Peptide Vaccines in Melanoma—Current Landscape and Future Direction
Qin, J. J., Wang, Y., & Sandhu, S. (2026) · Cells · doi:10.3390/cells15040344 · Cited by 5
“Administering immunotherapy in the neoadjuvant setting, when the tumour bulk and corresponding draining lymph node basins are in situ, has been shown to induce a stronger and more diverse T-cell response, leading to significantly improved clinical outcomes [85,86].”
The Application of PD ‐1 Inhibitors in Immunotherapy for Glioblastoma
Dong, M., Cui, M., Qu, L.-Z., Che, H., & Guan, H.-J. (2026) · The FASEB Journal · doi:10.1096/fj.202502901r · Cited by 5
“Thus, it is evident that the failure of anti- PD-1 treatment in glioblastoma may also be attributed to this mechanism [32, 33].”
Engineering neoantigens to form immunogenic biopolymer particles targeting metastatic breast cancer
Pounraj, S., Chen, S., Triscott, H., Lam, A. K.-Y., Ma, L., & Rehm, B. H. A. (2024) · Applied Materials Today · doi:10.1016/j.apmt.2024.102238 · Cited by 6
Yu, Y., Chen, H., Huang, Z., Yuan, Z., Liu, L., Zhao, J., & Wei, Q. (2024) · Otolaryngology · doi:10.1002/ohn.867 · Cited by 5
Jurascheck, L., Yang, Y.-H., Jackson‐Spence, F., Toms, C., Sng, C. C. T., Flanders, L., Bex, A., Powles, T. B., & Szabados, B. E. (2024) · World Journal of Urology · doi:10.1007/s00345-024-05133-8 · Cited by 5
Morgenthaler, J., Trommer, M., Khor, R., Wada, M., Bahig, H., Garden, A. S., Thai, A. A., Gan, H. K., Fokas, E., & Ng, S. P. (2024) · Oral Oncology · doi:10.1016/j.oraloncology.2024.107089 · Cited by 5
Sheng, Z., Ji, S., Chen, Y., Mi, Z., Yu, H., Zhang, L., Wan, S., Song, N., Shen, Z., & Zhang, P. (2025) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezaf132 · Cited by 6
Khan, M. T., Thompson, J., Kiiskila, L., Oboh, O., Truong, T., Prentice, A., Assifi, M. M., Chung, M. H., & Wright, G. P. (2022) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2022.10.022 · Cited by 5
Role of Neoadjuvant Immune Checkpoint Inhibitors in Resectable Non-Small Cell Lung Cancer
Riaño, I., Abuali, I. A., Sharma, A., Durant, J. A., & Dragnev, K. H. (2023) · Pharmaceuticals · doi:10.3390/ph16020233 · Cited by 5
“neoadjuvant immunotherapy used a breast carcinoma mouse model to demonstrate that neoadjuvant ICI and surgical resection was able to eradicate metastatic disease, unlike what had been seen with surgical resection and adjuvant disease [24].”
BackgroundMethodYin, C., Hu, B., Yang, X., Kou, L., Tian, B., Wang, C., Li, S., Liu, B., & Ge, J. (2023) · World Journal of Surgical Oncology · doi:10.1186/s12957-023-03194-4 · Cited by 5
Cancer immuotherapy for hepatocellular carcinoma
Lee, J.-H., Oh, S., Kim, J. Y., & Nishida, N. (2018) · Hepatoma Research · doi:10.20517/2394-5079.2018.78 · Cited by 5
Wen, T., Su, C., Xu, C., Wang, Y., Ma, T., Bai, Z., Zhang, H., & Liu, Z. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02765-9 · Cited by 5
Çetin, B., Wabl, C. A., & Gümüşay, Ö. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-00966-0 · Cited by 5
Indini, A., Lombardo, M., Sidoni, A., Gianatti, A., Mandalà, M., & Massi, D. (2022) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000375 · Cited by 5
Liu, S. M., Chen, Q., Zhou, C., Zhang, H., Li, W., Chen, J., Hu, J., Wu, L., Chen, Q., Dai, Q., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03412-8 · Cited by 5
Latest Advances in Perioperative care for Resectable Non-small lung cancer
Oya, Y., & Tanaka, I. (2025) · Respiratory Investigation · doi:10.1016/j.resinv.2025.04.001 · Cited by 5
Fjørtoft, M. O., Garred, Ø., Lingjærde, O. C., Lande, K. T., Ottestad, L., Bergheim, I. R., OSBREAC, Naume, B., Sahlberg, K. K., Borgen, E., et al. (2025) · BJC Reports · doi:10.1038/s44276-025-00152-3 · Cited by 5
Sun, M., Yang, P., Yang, T., Zhang, J., Li, H., Li, Y., & Zhu, B. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1611284 · Cited by 4
Impact of Tumor Burden on Immune Checkpoint and Conventional Therapy Responses and Outcomes
Gowda, P., Govindu, S. R., & Hsiehchen, D. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0327 · Cited by 4
“In addition, emerging evidence indicates that tumor burden is necessary for immunologic priming so that antigenic stimulation is sufficient to initiate a robust and durable immune response (12, 13).”
Tang, Z., Huang, T., & Yang, T.-L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311596 · Cited by 5
“This approach establishes lasting tumor-specific immune memory, offering ongoing protection against micro-metastatic disease [12,13].”
PD-1 inhibitor improves radiosensitivity by tumor vessel normalization
Hao, S., Ai, D., Wang, Q., Zhang, X., Ma, X., Tseng, I., Shen, J., Chen, Y., Liu, Q., Deng, J., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03315-8 · Cited by 5
Wu, H., Jiang, Q., Li, X., Ye, P., Rusidanmu, A., Li, N., Teng, X., Wang, Q., Chen, Y., Huang, D., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-025-01248-2 · Cited by 5
“However, the long-term outcome remains poor for neoadjuvant chemoradiotherapy (nCRT) or neoadjuvant chemotherapy (nCT) followed by esophagectomy, with recurrence occurring in 40% − 50% of patients 5 .”
Sabatino, V., Pignata, A., Valentini, M., Fantò, C., Leonardi, I., & Campora, M. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-33602-7_5 · Cited by 4
Advances in Adjuvant and Neoadjuvant Therapy for Melanoma
Sierra-Davidson, K., & Boland, G. M. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.05.007 · Cited by 5
Kudo, M. (2024) · Liver Cancer · doi:10.1159/000542221 · Cited by 5
Raimann, S., Schär, S., Hayoz, S., Gückenberger, M., Finazzi, T., Opitz, I., Schmid, S., Mark, M. T., Addeo, A., Mauti, L. A., et al. (2025) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2025.100834 · Cited by 4
Tostes, F. T., Zugman, M., Paes, V. R., & Schvartsman, G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.836751 · Cited by 4
“Pre-clinical and clinical data have postulated that early use of ICI may lead to improved efficacy, possibly due to a less immunosuppressive environment and enhanced priming of T-cells with the primary tumor’s antigens still present (6).”
BackgroundWang, Q., Chen, Q., Luo, J., Xu, N., Xu, M., Qiang, Y., Zhang, C., & Shen, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1239451 · Cited by 4
Feng, Y., Guo, K., Jin, H., Jiang, J., Wang, M., & Lin, S. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2325404 · Cited by 5
“This may be attributed to a higher tumor antigen load in the body before tumor resection, leading to the activation of more tumor-specific T cells in the systemic circulation [42].”
BackgroundWang, D., Liu, H., Tian, J.-C., Zhang, D.-L., Yan, L., Ding, Z., Li, H., Yan, Y., Dong, Z., & Li, T. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001357 · Cited by 5
Neoadjuvant Therapy in Melanoma
Farooq, M. S., Tidwell, J. C., & Karakousis, G. C. (2024) · Surgical Clinics of North America · doi:10.1016/j.suc.2024.11.005 · Cited by 4
Wellhausen, J., Röhl, L., Berszin, M., Krücken, I., Zebralla, V., Pirlich, M., Stoehr, M., Wiegand, S., Dietz, A., Wald, T., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1473897 · Cited by 4
Stoff, R., Yalon, M., Thorpe, M. P., Flotte, T. J., Block, M. S., & Hieken, T. J. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-18191-y · Cited by 4
“8 Preliminary preclinical data suggested that neoadjuvant Accuracy of PET–CT to … immunotherapy is more effective than adjuvant therapy, 9 based on the hypothesis that the existence of a macroscopic tumor with tumor infiltrating lymphocytes is a better substrate for immunotherapy to mount a durable…”
Metastasectomy in Advanced Renal Cell Carcinoma: A Systematic Review
Achkar, T., Maranchie, J. K., & Appleman, L. J. (2019) · Kidney Cancer · doi:10.3233/kca-180042 · Cited by 4
Janisch, F., Rink, M., & Shariat, S. F. (2020) · British Journal of Urology · doi:10.1111/bju.15025 · Cited by 5
Hanna, C. R., O'Cathail, S. M., Graham, J. S., Adams, R., & Roxburgh, C. S. D. (2021) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-20-31 · Cited by 5
“Liu et al [94] demonstrated stronger expansion of tumor-specific CD8 þ T cells in blood and peripheral organs after neoadjuvant treatment with anti-PD-1 and anti-CD137 therapies in a mouse breast cancer model, compared with post-surgery.”
Background[Application of Neoadjuvant Immuno-chemotherapy in NSCLC].
Chen, S., Zhao, Z.-R., & Long, H. (2021) · PubMed Central · doi:10.3779/j.issn.1009-3419.2021.102.10 · Cited by 6
Lymphoplasmacyte-rich meningioma in the central nervous system: An unusual case report
Wang, H., He, B., Wang, Y., Chen, H., Huang, S., & Xu, J. (2021) · Medicine · doi:10.1097/md.0000000000027991 · Cited by 4
The contemporary role of metastasectomy in the management of metastatic RCC
Feuer, Z. S., Taylor, J. I., & Huang, W. C. W. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.164 · Cited by 4
Wang, Y., Cao, Y., Wu, M., Lu, Y., He, B., Zhou, L., & Hu, W. (2021) · Interactive Cardiovascular and Thoracic Surgery · doi:10.1093/icvts/ivab321 · Cited by 4
“In addition, some studies have shown that preoperative neoadjuvant radiotherapy can promote the release of tumourassociated antigens [22].”
Chen, Y., You, Y., Wu, Q., Wu, J., Lin, S., Sun, Y., & Cui, Z. (2023) · Cancer Medicine · doi:10.1002/cam4.5813 · Cited by 4
Immunotherapies in non-metastatic gastrointestinal cancers
Saúde-Conde, R., Nguyen, D. J. M., & Hendlisz, A. (2023) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000956 · Cited by 4
“Preclinical mouse breast cancer models suggest that preoperative ICIs compared to postoperative improve T cell expansion and outcomes [12].”
BackgroundLi, J. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001680 · Cited by 5
“Neoadjuvant immunotherapy has the potential to clear these micrometastases, providing the chance for a cure [46] .”
BackgroundGaillard, S. L., Parker, J., Broadwater, G., Duska, L., Knochenhauer, H. E., Ring, K. L., McNally, L. J., Lee, P. S., Davidson, B., Previs, R., et al. (2026) · Gynecologic Oncology · doi:10.1016/j.ygyno.2026.06.003 · Cited by 4
Holder, A. M., Wargo, J. A., & Ross, M. I. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-14133-8 · Cited by 7
Britton, C. J., Andrews, J. R., Wallis, C. J. D., Sharma, V., Leibovich, B. C., Thompson, R. H., Boorjian, S. A., Bhindi, B., & Costello, B. A. (2022) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2022.09.021 · Cited by 3
Changes in the surgical management of melanoma and measures to implement change
McCahill, L. E. (2024) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2024.116129 · Cited by 3
Evolving roles of systemic therapy in hepatocellular carcinoma: neoadjuvant and adjuvant strategies
Chun, H. S., Lee, M., & Kim, T. H. (2025) · Journal of Liver Cancer · doi:10.17998/jlc.2025.06.13 · Cited by 4
“12-14 Compared to the adjuvant setting, neoadjuvant immunotherapy is hypothesized to elicit a more pronounced and durable immune response, potentially resulting in superior long-term clinical outcomes.”
Aoki, M., Kamimura, G., Tsuneyoshi, Y., Morizono, S., Tokunaga, T., Harada-Takeda, A., Maeda, K., Nagata, T., Kariatsumari, K., & Ueda, K. (2025) · Anticancer Research · doi:10.21873/anticanres.17755 · Cited by 3
“Liu et al. showed that the therapeutic effect of neoadjuvant ICI therapy was signi f icantly stronger than that of adjuvant ICI therapy in a mouse model of metastatic breast cancer (34).”
Zhang, S., Hu, A., Sun, J., Wei, Y., Zhang, J., 蔡海波, & Wang, G. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1711095 · Cited by 3
Guo, X., Li, P., Wu, W., Wang, Y., Qiu, J., Ma, Q., Guo, X., Liu, K., Wang, Y., Ruan, W., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1795426 · Cited by 3
Stage II Non-Small Cell Lung Cancer: Upfront Surgery or Neoadjuvant Chemoimmunotherapy
Tajè, R., Gallina, F. T., & Spicer, J. D. (2026) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2026.05.037 · Cited by 3
Liu, Y., Sun, S., Chu, Z., Liu, C., Chen, L., & Ruan, Z. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1324392 · Cited by 3
Neoadjuvant Immunotherapy in Non-melanoma Skin Cancers of the Head and Neck
Ezzibdeh, R. M., Diop, M., & Divi, V. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01197-1 · Cited by 3
“One presumed reason for improved neoadjuvant response is that tumor resection leads to a decrease in the neoantigens that promote a tumor-specific CD8 T-cell activation [30].”
Towards a new approach in pleural mesothelioma: Perioperative immunotherapy and its implications
Ambrosini, P., Stanzi, A., Russo, G. L., Solli, P., & Occhipinti, M. A. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104864 · Cited by 4
Cui, S., Zhao, K., Wang, N., Meng, Y. G., Zhao, C., Liu, H., Wen, X., & Kong, F. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01353-1 · Cited by 3
Impact of genomics on the surgical management of melanoma
Ferguson, P. M., Long, G. V., Scolyer, R. A., & Thompson, J. F. (2018) · British journal of surgery · doi:10.1002/bjs.10751 · Cited by 5
The path forward for anti-programmed cell death-1 therapy in gliomas
Majd, N., Kamiya-Matsuoka, C., & de Groot, J. (2019) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000746 · Cited by 3
“In metastatic breast cancer models in mice, neoadjuvant depletion of immunosuppressive T-regulatory (Treg) cells prior to resection resulted in elevated and sustained peripheral tumor-specific immune responses and improved survival of animals in comparison with adjuvant immunotherapy [25].”
BackgroundOrganerhalt beim fortgeschrittenen Larynx‑/Hypopharynxkarzinom: Erfahrungen aus der DELOS-II-Studie
Dietz, A., Wichmann, G., Kuhnt, T., & Wiegand, S. (2020) · HNO · doi:10.1007/s00106-020-00890-5 · Cited by 3
Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context
Gullapalli, S., Remón, J., Hendriks, L. E. L., & Lopes, G. D. L., Jr. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s259308 · Cited by 3
In Vivo Imaging to Measure Spontaneous Lung Metastasis of Orthotopically-injected Breast Tumor Cells
Sanon, S., & Bos, P. D. (2022) · Journal of Visualized Experiments · doi:10.3791/64002 · Cited by 3
Ascierto, P. A., Cioli, E., Chiarion‐Sileni, V., Quaglino, P., Spagnolo, F., Guidoboni, M., Vecchio, M. D., Peris, K., Queirolo, P., Fioretto, L., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1107307 · Cited by 4
“suggest that neoadjuvant administration of ICB is associated with improved survival and enhanced and long-lasting anti-tumor immune response compared with the same therapy administered in the adjuvant setting (22).”
BackgroundCurrent Management of Stage IIIA (N2) Non-Small-Cell Lung Cancer
Bryan, D. S., & Donington, J. S. (2023) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2023.01.006 · Cited by 4
The Evolving Role for Systemic Therapy in Resectable Non-small Cell Lung Cancer
Grant, M. J., Woodard, G. A., & Goldberg, S. B. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.02.003 · Cited by 3
Neoadjuvant Nivo/Rela for Resectable Melanoma
Miller, D. M., Kaufman, H. L., Emerick, K. S., Ear, M. E. A., Cohen, J. V., Kim, E., & Shalhout, S. Z. (2022) · Journal of Cutaneous Oncology · doi:10.59449/joco.2022.12.05 · Cited by 3
Role of Neoadjuvant Therapy Prior to Curative Resection in Hepatocellular Carcinoma
Whitham, Z. A., & Hsiehchen, D. (2023) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2023.07.003 · Cited by 3
Does perioperative immunotherapy reduce the risk of second primary cancers?
Tagliamento, M., Remón, J., Planchard, D., & Besse, B. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113355 · Cited by 3
Dong, H., & Yang, C. (2024) · The Clinical Respiratory Journal · doi:10.1111/crj.13756 · Cited by 4
“24 25 – 27 In this study, the meta-analysis we collected from the relevant published literature at home and abroad and results of 12 studies were combined and analyzed to increase the sample size and improve the power of the test.”
BackgroundCzarnecka, A. M., Ostaszewski, K., Błoński, P. J., Szumera‐Ciećkiewicz, A., Kozak, K., Placzke, J., Borkowska, A. M., Terlecka, A. M., Rogala, P., Świtaj, T., et al. (2024) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2024.108382 · Cited by 3
Vaccine a promising immunotherapy option for head and neck cancer patients
Mohsin, S. F. (2024) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.40.7.8791 · Cited by 3
Hesham, A., Alotaibi, F. H., Kim, D. D., Alshamrani, Y., Hyppolito, J. O. P., & Jubala, K. (2024) · Oral Oncology Reports · doi:10.1016/j.oor.2024.100596 · Cited by 3
History of cancer and transplant clearance: Considerations prior to transplantation
Esmail, A., & Abdelrahim, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21901-6.00018-5 · Cited by 5
Kinsey, E. N., & George, D. J. (2019) · European Urology Focus · doi:10.1016/j.euf.2019.05.013 · Cited by 3
Metastatic melanoma: therapeutic agents in preclinical and early clinical development
Boos, L. A., Leslie, I., & Larkin, J. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1769066 · Cited by 3
Sun, L., & Aggarwal, C. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000485 · Cited by 3
Assessing the Efficacy of Immune Checkpoint Inhibitors in Preclinical Tumor Models
Jacoberger-Foissac, C., Allard, B., Allard, D., & Stagg, J. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-2914-7_11 · Cited by 3
Karachaliou, N., & Rosell, R. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918763723 · Cited by 3
Locally Advanced Kidney Cancer: A New Space for Immunotherapy?
Singla, N., & Margulis, V. (2021) · European Urology Oncology · doi:10.1016/j.euo.2021.05.003 · Cited by 3
Perioperative Considerations of Breast Cancer Neoadjuvant Treatments
Brumer, R. P., & Angarita, F. A. (2025) · Clinical Breast Cancer · doi:10.1016/j.clbc.2025.03.004 · Cited by 2
Zeng, L., Zhang, Y., Zeng, A., & Ma, D. (2025) · Cancer Management and Research · doi:10.2147/cmar.s517837 · Cited by 2
“20 Clinical studies have observed that the number of CD8+ T cells in tumor infiltrating lymphocytes in patients with gastric cancer who received immunotherapy before radiotherapy was higher than that in patients without immunotherapy.”
Neoadjuvant immunotherapy for resectable primary liver cancer (Review)
Deng, Q., He, M., Zhang, L., & Wu, Y. (2025) · Oncology Letters · doi:10.3892/ol.2025.15204 · Cited by 2
“A preclinical model reported that, compared with postoperative treatment only, PD‑1 blockade before surgery improved the survival rate and enhanced the activation of tumor‑specific CD8 + T cells in mice (50).”
He, Y., Huixing, L., & Liping, W. (2025) · Clinical Breast Cancer · doi:10.1016/j.clbc.2025.11.017 · Cited by 2
Chen, G., Yao, Y., Liu, Y., Sun, Y., Gao, Y., Zhang, J., Wei, S., Li, C., Li, D., Zhou, Y., et al. (2026) · International Journal of Surgery · doi:10.1097/js9.0000000000004836 · Cited by 2
PROTAC-based protein degradation: a window of opportunity for melanoma therapy
Gentile, G., D’Aguanno, S., Martile, M. D., Petricca, A., Valentini, E., Scalera, S., & Bufalo, D. D. (2026) · Journal of Biomedical Science · doi:10.1186/s12929-026-01225-2 · Cited by 2
“Neoadjuvant treatment, in which surgery follows the immunotherapy, could represent an alternative approach to, or even replace, the adjuvant treatment: several pre-clinical studies and clinical trials support this possibility [88, 89] .”
Abodunrin, F., Cameron, R. B., Haque, W. Z., Bestvina, C. M., & Garassino, M. C. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1779081 · Cited by 3
Wang, J., Song, P., Ge, Y., Yang, H., Li, S., Ma, R., Ma, T., Feng, S., Zhang, C., Sun, T., et al. (2026) · International Journal of Cancer · doi:10.1002/ijc.70473 · Cited by 2
“…benefits over adjuvant immunotherapy, such as tumor downstaging and the earlier targeting of micrometastatic lesions, potentially resulting in resections that were previously considered unattainable or too extensive, thereby improving surgical outcomes and prolonging postoperative survival [9–11].”
Bila, M., Poorten, V. V., Meulemans, J., Huvenne, W., Vos, W. D., Willaert, R., Ceulaer, J. D., & Clément, P. M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1799437 · Cited by 2
“In preclinical models, neoadjuvant immunotherapy outperformed adjuvant delivery for eradicating metastatic disease, linked to expansion and systemic dissemination of tumor-speci fi c T cells (10).”
Angulo-Lozano, J. C., Calderon, L. P., Liu, H., Blanchard, L., Wahba, B. M., Suzman, E., Iranmahboub, P., Blum, K. A., Dave, P., Calvillo-Ramirez, A., et al. (2026) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2026.04.291 · Cited by 2
Pan, Y., Yang, X., Zhou, Q., Zhao, Y. W., Han, G., Pang, Q., Zhang, Z., Wang, Q., Yao, J., Wang, H., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02779-1 · Cited by 2
“24,25 While the utility of induction chemotherapy has historically been constrained by suboptimal complete resection rates, the integration of neoadjuvant immunotherapy has been shown to improve complete resection rates.”
Kampel, L., Bordovski, Y., Warshavsky, A., Shilo, S., Horowitz, G., Finkel, I., Gutfeld, O., & Muhanna, N. (2026) · Oral Oncology · doi:10.1016/j.oraloncology.2026.108098 · Cited by 2
Gunster, J. L. B., Tramm, T., Machiels, M., Demaria, S., Formenti, S. C., Caluwé, A. D., Duane, F. K., Klein, J., Sur, D. G., Somaiah, N., et al. (2026) · The Lancet Oncology · doi:10.1016/s1470-2045(26)00255-x · Cited by 2
Challenges and Opportunities of Neoadjuvant Treatment in Locally Advanced Melanoma
McKean, M. A., & Amaria, R. N. (2018) · American Journal of Clinical Dermatology · doi:10.1007/s40257-018-0371-8 · Cited by 2
The great debate at “Melanoma Bridge 2018”, Naples, December 1st, 2018
Ascierto, P. A., Bruzzi, P., Eggermont, A. M. M., Hamid, O., Tawbi, H. A., van Akkooi, A. C. J., Testori, A., Caracò, C., Puzanov, I. J., & Perrone, F. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1892-5 · Cited by 2
Is there a role for neoadjuvant anti-PD-1 therapies in glioma?
Sun, L., Lai, T. J., & Prins, R. M. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000992 · Cited by 3
Preoperative Immunotherapy for Prostate Cancer: From Bench to Bedside
Drake, C. G. (2022) · Springer eBooks · doi:10.1007/978-3-030-80546-3_11 · Cited by 2
Park, S. (2023) · The Korean Journal of Thoracic and Cardiovascular Surgery · doi:10.5090/jcs.23.009 · Cited by 3
Metadata
- Authors
- Liu, J., Blake, S. J., Yong, M. C. R., Harjunpää, H., Ngiow, S. F., Takeda, K., Young, A., O'Donnell, J. S., Allen, S., Smyth, M. J., & Teng, M. W. L.
- Affiliations
- The University of Queensland (AU)
- QIMR Berghofer Medical Research Institute (AU)
- Juntendo University (JP)
- 1Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
- Corresponding author
- Teng, Michele W.L.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2016-12-01
- Volume
- 6
- Issue
- 12
- Pages
- 1382-1399
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2521503673
- Cited by
- 894
- References
- 55
- Citations by year
- 2026: 86 · 2025: 91 · 2024: 135 · 2023: 112 · 2022: 113 · 2021: 112 · 2020: 101 · 2019: 65 · 2018: 50 · 2017: 23 · 2016: 1
- FWCI
- 24.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (15K14410)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- neoadjuvant immunotherapy, adjuvant immunotherapy, metastatic breast cancer, primary tumor resection, tumor-specific immunity, CD8+ T cells, predictive biomarkers
- MeSH terms
- Animals, Antibodies, Monoclonal, Antineoplastic Agents, Breast Neoplasms, Female, Humans, Immunotherapy, Neoplasm Metastasis, Treatment Outcome, Chemotherapy, Adjuvant, CD8-Positive T-Lymphocytes, Neoadjuvant Therapy, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.